Medicare Enrolled

Dr. Jose Lutzky, M.D.

Hematology & Oncology · Miami, FL
Practice pattern: Clinical Cardiology— Primarily office-based clinical cardiology
Speaking/Promotional
1475 NW 14TH AVE, Miami, FL 33125
3056896500
In practice since 2005 (20 years)
NPI: 1235127929 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Lutzky from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lutzky? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Lutzky

Dr. Jose Lutzky is a hematology & oncology in Miami, FL, with 20 years in practice. Based on federal Medicare data, Dr. Lutzky performed 238 Medicare services across 118 unique beneficiaries.

Between the years covered by Open Payments, Dr. Lutzky received a total of $69,507 from 55 pharmaceutical and/or device companies across 575 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. The majority of payments are for speaking programs and promotional activities, reflecting participation in industry-sponsored events. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Lutzky is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years in practice▲ 238 Medicare services$ $69,507 industry payments

Medicare Practice Summary

Medicare Utilization ↗
238
Medicare services
Bottom 23% in FL for hematology & oncology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
118
Unique beneficiaries
$78
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~12 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Office visit, established patient (30-39 min)213$81$299
Office visit, established patient (20-29 min)25$56$193
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.

Industry Payment Transparency

Open Payments through 2024 ↗
$69,507
Total received (2018-2024)
Avg $9,930/year across 7 years
Top 12% in FL for hematology & oncology
55
Companies
575
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$50,576 (72.8%)
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$10,414 (15.0%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,516 (12.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$6,518
2023
$705
2022
$3,743
2021
$1,728
2020
$3,309
2019
$23,761
2018
$29,743

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
Novartis Pharmaceuticals Corporation
$16,211
GENZYME CORPORATION
$12,146
Regeneron Healthcare Solutions, Inc.
$11,292
Array BioPharma Inc.
$8,707
Regeneron Pharmaceuticals, Inc.
$5,631
ARRAY BIOPHARMA INC
$3,682
Incyte Corporation
$2,341
Eisai Inc.
$1,677
E.R. Squibb & Sons, L.L.C.
$1,047
Merck Sharp & Dohme Corporation
$757
PFIZER INC.
$701
Genentech USA, Inc.
$619
Janssen Biotech, Inc.
$538
EMD Serono, Inc.
$513
AstraZeneca Pharmaceuticals LP
$423
TriSalus Life Sciences, Inc.
$360
Lilly USA, LLC
$294
Amgen Inc.
$240
Celgene Corporation
$239
Janssen Scientific Affairs, LLC
$207
Takeda Pharmaceuticals U.S.A., Inc.
$150
Sirtex Medical Inc
$143
Immunocore Limited
$135
Janssen Pharmaceuticals, Inc
$132
Merck Sharp & Dohme LLC
$113
Seattle Genetics, Inc.
$113
SEAGEN INC.
$100
Clinigen, Inc.
$89
MEDIVATION FIELD SOLUTIONS LLC
$83
AbbVie, Inc.
$76
Bayer HealthCare Pharmaceuticals Inc.
$74
Pharmacyclics LLC, An AbbVie Company
$56
TESARO, Inc.
$55
Astellas Pharma US Inc
$48
Daiichi Sankyo Inc.
$46
EISAI INC.
$43
Teva Pharmaceuticals USA, Inc.
$41
Clovis Oncology, Inc.
$40
AMAG Pharmaceuticals, Inc.
$39
Foundation Medicine, Inc.
$35
Agios Pharmaceuticals, Inc.
$27
Sun Pharmaceutical Industries Inc.
$22
Boehringer Ingelheim Pharmaceuticals, Inc.
$21
GlaxoSmithKline, LLC.
$21
Tempus AI, Inc
$20
Gilead Sciences, Inc.
$19
Genmab U.S., Inc.
$18
Verastem, Inc.
$18
Medtronic USA, Inc.
$17
Otsuka America Pharmaceutical, Inc.
$17
Ipsen Biopharmaceuticals, Inc
$15
Aurobindo Pharma USA, Inc.
$15
Myriad Genetic Laboratories, Inc.
$15
SANOFI-AVENTIS U.S. LLC
$12
Taiho Oncology, Inc.
$11
Top 3 companies account for 57.0% of total payments
Associated products mentioned in payments ›
ADCETRIS · ALIMTA · ALUNBRIG · Abraxane · Alecensa · Aliqopa · Aranesp · BAVENCIO · BENDEKA · BOSULIF · BRACANALYSIS CDX · BRAFTOVI · Bavencio · Braftovi · CALQUENCE · CYRAMZA · Copiktra · DARZALEX · ELIQUIS · ELITEK · EMEND · EMPLICITI · ENHERTU · ERBITUX · Enhertu · Epkinly · Erivedge · Erleada · FERAHEME · FOUNDATIONONE · Folotyn · GAZYVA · GILOTRIF · Halaven · IBRANCE · IDHIFA · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JADENU · JAKAFI · KEYTRUDA · KIMMTRAK · KISQALI · Kyprolis · LIBTAYO · LIBTAYO CEMIPLIMAB-RWLC INJECTION · LORBRENA · LYNPARZA · Lenvima · Lonsurf · MEKINIST · NO PRODUCT DISCUSSED · Neulasta · OPDIVO · PIQRAY · PROMACTA · Perjeta · Proleukin · Prolia · RYBREVANT · RYDAPT · Revlimid · Rituxan Hycela · Rubraca · SANDOSTATIN · SIR-Spheres Microspheres · SOMATULINE DEPOT · SPRYCEL · SUTENT · SYNCHROMED · TAFINLAR · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TRINAV INFUSION SYSTEM · VELCADE · VENCLEXTA · VERZENIO · VOTRIENT · Venclexta · XARELTO · XT CDX · XTANDI · Xofigo · YONSA · ZEJULA · Zelboraf
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (73%) are for speaking programs and promotional activities, which reflect participation in industry-sponsored educational or marketing events. This is common in hematology & oncology and does not inherently indicate bias, but patients may wish to be aware.

Equivalent to $29,204 per 100 Medicare services performed
Looking for a hematology & oncology in Miami?
Compare hematology & oncologys in the Miami area by procedure volume, costs, and industry payment transparency.
Browse hematology & oncologys nearby

Geographic Context

Hematology & Oncologys within 10 mi
179
Per 100K population
6.7
County median income
$68,694
Nearest hospital
MIAMI VA MEDICAL CENTER
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Lutzky is a clinical cardiology specialist, with moderate Medicare volume, and high industry engagement (speaking/promotional, top 12%), with 20 years of practice experience.

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Lutzky experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Lutzky performed 213 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Lutzky receive payments from pharmaceutical companies?
Yes. Dr. Lutzky received a total of $69,507 from 55 companies across 575 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lutzky's costs compare to other hematology & oncologys in Miami?
Dr. Lutzky's average Medicare payment per service is $78. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lutzky) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →